This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2024-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2025
Title: Daniel Jeremy Turley - Innovator in HBV Treatment
Introduction
Daniel Jeremy Turley is an inventor based in Basel, Switzerland. He is currently associated with F. Hoffmann-La Roche AG, a leading global healthcare company. Although he has not yet been granted any patents, his work focuses on innovative solutions for medical challenges, particularly in the field of viral infections.
Latest Patent Applications
Daniel Jeremy Turley has filed a patent application titled "Oligonucleotides for Modulating RTEL1 Expression." This invention relates to a RTEL1 inhibitor intended for the treatment of HBV infections, especially chronic HBV infections. The application emphasizes the use of RTEL1 inhibitors to destabilize cccDNA, such as HBV cccDNA. Additionally, it includes antisense oligonucleotides that are complementary to RTEL1 and capable of reducing RTEL1 mRNA. The invention also encompasses a pharmaceutical composition and its application in the treatment and/or prevention of HBV infections.
Conclusion
Daniel Jeremy Turley is making significant strides in the field of medical innovation, particularly in the treatment of HBV infections. His ongoing research and patent applications reflect his commitment to advancing healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile